Assyro AI

Orange Book product · Brand (NDA)

DAPTOMYCIN

DAPTOMYCIN

Brand (NDA)NDA 210282RX HOSPIRA

At a glance

Jun 21, 2021

Approved

Brand (NDA)

Application

Not listed

TE code

2

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jun 21, 2021

    5 yr 1 mo ago

  2. Today

  3. Patent 10357535 expires

    Listed drug product patent expiration.

    Sep 11, 2033

    in 7 yr 4 mo

  4. Patent 9655946 expires

    Listed drug product patent expiration.

    Sep 11, 2033

    in 7 yr 4 mo

Pharmaceutical detail

Active ingredient

DAPTOMYCIN

Strength

500MG/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 210282

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (2)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10357535Sep 11, 2033in 7 yr 4 mo
ProductU-3176
9655946Sep 11, 2033in 7 yr 4 mo
ProductU-3175
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.